期刊
SEMINARS IN CANCER BIOLOGY
卷 13, 期 6, 页码 409-415出版社
ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2003.09.004
关键词
melanoma; cancer vaccines; adjuvant therapy; immunotherapy; HLA antigens
类别
The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine((R))( is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX(R). Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine((R)) in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed. (C) 2003 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据